This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

More Hep C Drug Abstracts Leak Ahead of EASL Confab

Stock quotes in this article: BMY, GILD, ABT, IDIX, VRTX, JNJ

BOSTON ( TheStreet) -- More hepatitis data supposedly kept under wraps by the European Association for the Study of the Liver (EASL) in advance of next week's closely followed annual meeting has made its way into the hands of Wall Street investors.

Fortunately for EASL, the leaked research abstracts, including one describing the important "Electron" study of Gilead Sciences' (GILD) hepatitis C drug GS-7977, doesn't contain new information and therefore isn't particularly stock moving.

On Tuesday, an investor who asked to remain anonymous emailed me three research abstracts involving hepatitis C drug data from Gilead Sciences and Bristol-Myers Squibb (BMY). All of the abstracts were supposed to be embargoed and therefore not publicly available, according to EASL rules.

One of these abstracts, titled "Electron: Once Daily PSI-7977 Plus RBV in HCV GT1/2/3" is the subject of intense investor interest because it will help assess the efficacy of Gilead's most important hepatitis C drug, acquired through the $11 billion acquisition of Pharmasset.

EASL officials confirmed the authenticity of the leaked research abstracts via email but requested that specific information contained in the abstracts not be disclosed. I'm abiding by EASL's request because the leaked abstracts are not much more than placeholders containing early, incomplete and previously announced data that will only be updated at the EASL meeting April 18-22.

The embargoed abstract for Gilead's Electron study, for example, describes but doesn't contain any specific data on response rates involving GS-7977 and treatment-naive, genotype 1 hepatitis C patients. The performance of GS-7977 in this group of hepatitis C patients is among the most highly anticipated data presentations expected at the EASL meeting.

The EASL meeting is where Gilead Sciences, Bristol, Abbott (ABT), Idenix Pharmaceuticals (IDIX), Vertex Pharmaceuticals (VRTX) and Johnson & Johnson (JNJ) are among the companies expected to present new clinical data on experimental hepatitis C therapies. Therefore, the meeting is as vitally important to hepatitis C doctors and patients as it is to investors.

How a select set of confidential, embargoed hepatitis C drug abstracts came into the hands of some Wall Street investors hasn't been fully explained. The blame most likely lies with EASL, which apparently failed to wall off the select set of abstracts when the group posted most of the abstracts online April 4. EASL later realized its error and was able to yank the embargoed abstracts from its web site, but not before some people, including some investors, were able to download them.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,042.90 -28.32 -0.17%
S&P 500 1,972.29 -5.51 -0.28%
NASDAQ 4,493.39 -12.4620 -0.28%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs